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INTRODUCTION
Pulmonary MRI has historically had limited clinical impact 
due to the poor image signal- to- noise and short T2* caused 
by magnetic susceptibility differences between air and 
lung parenchyma. Whilst CT remains the gold- standard 
for structural lung imaging in many clinical indications, 
the advent of ultrashort and zero echo time (UTE/ZTE) 
acquisition techniques has enabled 1H pulmonary MRI to 
advance to a point such that it is now recommended clin-
ically for certain disorders.1 Hyperpolarised (HP) gases, 
3He and 129Xe, as inhaled MRI contrast agents offer a 
wealth of complementary information about the function 
and microstructure of the lung and have great potential 
as a clinical tool for early detection and understanding of 
patho- physiology of certain lung diseases. HP gas MRI is 
now poised to impact upon clinical management through 
safe, sensitive monitoring of disease progression and 
response to therapy.
In this invited review, we briefly introduce HP gas MRI 
techniques and what aspects of lung function they probe. 
Then, focusing on the substantial evidence base gathered to 
date, we review HP gas MRI studies in patients with a range 
of pulmonary disorders, including emphysema, asthma, 
cystic fibrosis, and interstitial lung disease. Finally, we 
review our experience of using the technique in Sheffield in 
a diagnostic clinical setting.
HP gas MRI methodology
Gases are intrinsically low spin density and conventional 
polarisation by the scanner’s magnetic field generally 
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ABSTRACT
The use of pulmonary MRI in a clinical setting has historically been limited. Whilst CT remains the gold- standard for 
structural lung imaging in many clinical indications, technical developments in ultrashort and zero echo time MRI tech-
niques are beginning to help realise non- ionising structural imaging in certain lung disorders. In this invited review, we 
discuss a complementary technique – hyperpolarised (HP) gas MRI with inhaled 3He and 129Xe – a method for functional 
and microstructural imaging of the lung that has great potential as a clinical tool for early detection and improved 
understanding of pathophysiology in many lung diseases. HP gas MRI now has the potential to make an impact on 
clinical management by enabling safe, sensitive monitoring of disease progression and response to therapy. With refer-
ence to the significant evidence base gathered over the last two decades, we review HP gas MRI studies in patients 
with a range of pulmonary disorders, including COPD/emphysema, asthma, cystic fibrosis, and interstitial lung disease. 
We provide several examples of our experience in Sheffield of using these techniques in a diagnostic clinical setting in 
challenging adult and paediatric lung diseases.
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results with thermally polarised fluorinated gases are emerging 
for imaging lung ventilation.2,3 However, for certain gases such 
as 3He and 129Xe, the MR signal can be boosted by 4—5 orders 
of magnitude through hyperpolarisation, typically achieved 
through spin- exchange optical pumping with a high- powered 
laser.4 Once hyperpolarised, these gases can be delivered to a 
patient in up to 1 L doses via a plastic bag. MR image acquisi-
tion is usually performed during a short breath- hold (<15 s) after 
inhalation from the bag, and throughout which vital signs are 
monitored.
We now briefly review the different aspects of lung function, 
physiology and microstructure that the method can be used to 
investigate.
Ventilation: Direct MR imaging of HP gas in the lungs provides a 
measure of gas density and allows the visualisation of the distri-
bution and heterogeneity of lung ventilation; i.e. the delivery of 
inspired gas to the alveoli and distal airways. Ventilation abnor-
malities/defects – signal voids in the image – reflect the absence 
of HP gas in affected regions of the lung and can be caused by 
obstruction or constriction of the airways.
Ventilation biomarkers: Ventilation defect percentage (VDP); 
the percentage of low/zero intensity pixels in the image, or its 
inverse, the ventilated volume percentage (VV%), are the most- 
commonly used biomarkers of ventilation (Figure 1a). Ventila-
tion heterogeneity can be further quantified by calculating the 
coefficient of variation (CV)5,6 (Figure 1b), or classifying pixels 
into defect, low, normal and high ventilation bins.7
Microstructure (Diffusion- weighted MRI): Both 3He and 129Xe 
gases are 4—5 orders of magnitude more diffusive than water 
molecules in bodily tissues, and are therefore well suited for 
diffusion- weighted MRI. Inhaled gas atoms diffuse in the acinar 
airspace through random Brownian motion, and encounter the 
alveolar walls several times over a time- scale of ~milliseconds 
(Figure  2a). This leads to a diffusion restriction dependent on 
the acinar microstructure, and which can be probed by HP gas 
diffusion- weighted MRI.
Biomarkers of microstructure: The apparent diffusion coefficient 
(ADC) can be mapped voxel- by- voxel providing regional infor-
mation on alveolar airspace size9; its mean value across the lungs 
provides a simple, sensitive biomarker (Figure  2b). Multiple 
b- value diffusion- weighted MRI with theoretical modelling of 
the complex gas diffusion signal allows quantification of various 
acinar airway morphological parameters including the surface- 
area- to- volume ratio, alveolar radii and mean diffusive length 
scale (LmD) (Figure 2c).10–12
Gas exchange (Dissolved- phase 129Xe MRI): Xenon is moder-
ately soluble in lung parenchyma and blood (Figure  3a) and 
129Xe exhibits distinct resonances in the tissue and blood plasma 
(TP) and separately, the red blood cells (RBCs) in the pulmonary 
capillaries that are chemically shifted from the gaseous 129Xe in 
the alveolar airspace.14 MR spectroscopy (MRS),15,16 chemical 
shift saturation recovery (CSSR)17 and chemical shift imaging 
techniques13,18 allow the investigation of gas exchange func-
tion by directly measuring the 129Xe MR signal in each of these 
compartments.
Gas exchange biomarkers: The signal ratios of 129Xe in different 
physiochemical compartments; RBC:TP, RBC:Gas, TP:Gas 
are used as quantitative gas exchange biomarkers (Figure  3b), 
and can be used to distinguish RBC transfer (indicative of true 
gas exchange) from parenchymal tissue thickening. Diffusion 
modelling of time resolved 129Xe spectroscopic techniques allows 
quantification of various alveolar morphological parameters.
A summary of the different imaging biomarkers that can be 
derived from HP gas MRI, and their reference values in healthy 
subjects, is presented in Table 1.
Practicalities of HP gas MRI
From a practical perspective, the following requirements must be 
met to perform HP gas MRI in a clinical setting: (1) regulatory- 
approved gas polariser (>£350k); (2) licence for gas manufacture 
Figure 1. a) Example HP gas ventilation image (red) overlaid 
on a 1H MRI anatomical image (green). VDP is derived by iden-
tifying low / no signal voxels (defects; pink) and calculating 
their volume percentage of the whole of the lungs as deter-
mined from 1H MRI. (b) HP gas ventilation images of the lungs 
of a healthy child and a child with CF, exhibiting homogene-
ous and heterogeneous ventilation, respectively. CV is derived 
by sliding a kernel (in this case 3 × 3) over the image and 
calculating the coefficient of variation for the central voxel in 
the window. The mean, median or interquartile range of the 
resulting CV histogram can be quoted. CF, cystic fibrosis; CV, 
coefficient of variation; HP, hyperpolarised; VDP, ventilation 
defect percentage.
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and inhalation (may initially be a research licence as an inves-
tigative medicinal product, but ultimately, approval from the 
MHRA, FDA or other regulatory body is needed for diagnostic 
use); (3) multinuclear (broadband) MRI scanner (1.5 T or 3 T) 
and vendor support; (4) radiofrequency transmit- receive coils 
for the nuclei of interest (>£35k); (5) NHS or other healthcare 
institution referral pathway.
From the perspective of raw materials, 129Xe- isotope enriched 
xenon costs around £180/L and doses of 500—1000 mL are typi-
cally needed. However, use of the 26% 129Xe natural abundance 
mixture is much cheaper (~£25/L) and provides adequate results 
for ventilation imaging (the most common clinically- requested 
scan in our institution).22 Whilst the initial outlay for several 
of these components can be significant, a scalable health- care 
economics model for patient scanning with HP 129Xe MRI is 
potentially achievable in the context of a regional hub in a large 
teaching hospital setting, when viewed alongside the NHS tariff 
costs for other specialist imaging and comprehensive lung func-
tion testing.
A HP gas lung MRI protocol can take around 15—30 min to 
complete, including the time required for set- up of the 3He 
or 129Xe radiofrequency coil. In total, between 2 and 5 doses 
of gas are typically delivered; one small dose (~few 10 of mL) 
for calibration of the acquisition parameters – including flip 
angle and Larmor resonance frequency of the gas nuclei – and 
the remaining main dose(s) (500—1000 mL) for ventilation, 
diffusion- weighted and/or dissolved- phase imaging. The choice 
of scans to perform depends on the diagnosis/symptoms of the 
patient, as discussed in the following sections. For example, in 
asthma, which is characterised by airway inflammation, venti-
lation imaging alone is usually sufficiently sensitive to airway 
obstruction and additional HP gas acquisitions may not add 
clinically significant information. In contrast, acquisition of 
dissolved- phase imaging data will be of a priority in patients 
where gas- exchange limitation is known/anticipated. The HP 
gas protocol is usually combined with a 1H pulmonary MRI 
protocol, which can take an additional 10—30 min to complete 
and may include some or all of the following: anatomical scans 
including spoiled gradient echo-, turbo spin echo or steady- 
state free precession- based sequences; ultrashort echo time 
scans for high- resolution structural imaging; non- contrast and/
or contrast- enhanced perfusion scans; dynamic 1H MRI and 
possibly oxygen- enhanced imaging. In our experience, these 
methods can be performed equally well on both 1.5 T and 3 T 
scanner platforms that are typical for the bulk of clinical practice, 
with the former generally more forgiving for thoracic applica-
tions.22–25 As the HP gas portion of the scan is most time critical 
(due to the dose timing of the hyperpolarisation process) and 
costly to repeat, it is conventional to perform this prior to the 
1H portion and certainly before any paramagnetic intravenous 
contrast agents have been administered. The signal enhancement 
induced by the hyperpolarisation process is non- permanent and 
Figure 2. (a) cartoon of HP gas diffusion in the lungs of a 
healthy subject and a patient with COPD; diffusion is more 
restricted in the former, while emphysematous tissue destruc-
tion leads to less- restricted (freer) diffusion in the latter, i.e. 
increased ADC. (b) HP 129Xe ADC maps, indicating signifi-
cantly increased ADC in a patient with COPD compared with 
a healthy subject. (c) representative diffusion- weighted HP 
129Xe MRI- derived morphological maps of the mean alveolar 
diffusion length scale, depicting increased alveolar size in 
patients with IPF and COPD in comparison to healthy subjects 
(adapted from8). As is clear from the ADC and LmD maps 
obtained from the lungs of the COPD patient in b) and c); 
these metrics can only be calculated for ventilated areas of 
the lung. ADC, apparent diffusion coefficient; COPD, chronic 
obstructive pulmonary disease; HP, hyperpolarised; IPF, idio-
pathic pulmonary fibrosis.
Figure 3. a) Schematic of xenon diffusion from the alveolar 
(gas) phase into the lung tissue and blood. (b) Simulated 129Xe 
MR spectra in healthy human lungs, indicating the chemically- 
shifted (δ) gas, TP and RBC resonances. In the inset, the differ-
ence in the dissolved phase (TP and RBC) part of the spectrum 
typically observed in the lungs of patients with IPF compared 
with healthy subjects is shown; notably, an increased TP reso-
nance relative amplitude and reduced RBC resonance relative 
amplitude. These chemically shifted signals can be separately 
imaged via chemical shift imaging pulse sequences to obtain 
signal ratio maps; c) representative signal ratio maps obtained 
from a patient with IPF; yellow arrows indicate a region of 
reduced RBC transfer (gas exchange) that was normally ven-
tilated (reproduced from Collier et al.13). IPF, diopathic pulmo-
nary fibrosis; RBC, red blood cell; TP, tissue and blood plasma.
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decays according to the longitudinal relaxation time (T1) of the 
gas. This is of the order of hours in an oxygen- free environment 
and a stable magnetic field, but reduces to ~10s of seconds in the 
lungs. Ideally, doses of HP gas should be stored in a magnetic 
field prior to delivery; it is practical to situate the polariser in a 
room proximal to the MR scanner or otherwise use a magnetic 
container to transport the gas over larger distances.
Both 3He and 129Xe are considered safe for inhalation in the 
relatively small dosages used for MRI. In 100 individuals with a 
range of lung conditions, Lutey et al reported no serious adverse 
events and no effect on vital signs from the 3He breath- hold 
MRI procedure, other than a small post- imaging decrease in 
mean heart rate and a transient mean decrease in SpO2 of ~4% 
within the first minute after inhalation.26 Unlike helium, xenon 
has anaesthetic properties at a sustained minimum alveolar 
concentration (MAC) of between 63 and 71%,27,28 however the 
doses and short breath- hold durations used in HP 129Xe lung 
MRI yield a transient alveolar concentration far below this. A 
number of safety and tolerability studies in adults and children 
with a variety of pulmonary disorders have reported no serious 
or severe adverse events after 129Xe breath- hold.29–31 As with 
3He, transient decreases in SpO2 of a few percentage points after 
129Xe breath- hold are commonly observed, but resolve within 
1—2 min. Many adult patients report mild transient symptoms 
including dizziness, paresthesia and euphoria that fully resolve 
within a few minutes after inhalation.29
We note that a significant proportion of the historical literature is 
occupied by research on 3He due to its relatively high gyromag-
netic ratio (high intrinsic MR signal). However, 3He is not natu-
rally abundant, its availability has become severely regulated, and 
costs have risen to the point that it is not an economically viable 
agent for widespread clinical use.32 For this reason, coupled with 
the fact that dissolved- phase MRI of pulmonary gas exchange is 
exclusively possible with 129Xe, which is of great clinical interest, 
the HP gas MRI field has generally transitioned to the use of 
129Xe over the last 5—10 years. A comparison of the key proper-
ties of the two gases relevant to their application in lung MRI is 
shown in Table 2; most notably highlighting the lower diffusivity 
of 129Xe.
Table 1. Summary of key clinical metrics that can be derived from HP gas MRI
Biomarker Description Healthy reference balues
VDP (VV) Ventilation defect percentage (Ventilated volume): percentage of total lung volume that is not 




CV (VHI) Coefficient of variation (Ventilation heterogeneity index): metrics of regional ventilation 
heterogeneity
Mean CV <15% (ref20)
IQR CV <10% (ref5) c
ADC Apparent diffusion coefficient: describes how far gas can diffuse in a given time before being 
impeded → metric of alveolar size
3He: 0.190 ± 0.017 cm2.s−1
129Xe: 0.038 ± 0.003 cm2.s−1
(ref6)
LmD Mean diffusive length scale: comparable to histology mean linear intercept → metric of alveolar 
size
3He: 212 ± 24 µm





Ratios of 129Xe signal in RBC vs tissue plasma vs gas phase (alveoli) of the lungs: RBC/TP: metric 
of gas exchange function and parenchymal tissue thickening; RBC/Gas: metric of gas exchange 





ADC, apparent diffusion coefficient; CV, coefficient of variation; IQR, interquartile range; ṢNR, signal- to- noise ratio; RBC, red blood cell; TP, tissue 
and blood plasma; VDP, ventilation defect percentage; VHI, Ventilation heterogeneity index; VV, ventilated volume.
aThese values are appropriate for the IDEAL method described in Collier et al13 (for other gas exchange imaging methods, values may differ, see 
e.g. Wang et al21)
bThese values depend on the exact analysis technique and are provided as a guide only.
cThese values vary with analysis technique, image SNR, and statistic (mean, median, IQR, etc.) chosen
Table 2. Key Properties of HP Gas Nuclei
Property 1H 3He 129Xe
Isotopic abundance (%) 99.99 1.4 × 10−4 26.44 (natural abundance)
80—90 (129Xe- enriched)
Gyromagnetic ratio (MHz/T) 42.58 −32.44 −11.78
Self- diffusion coefficient (cm2/s)a 2 × 10−5 2.05 0.06
Diffusion coefficient in air (cm2/s)a – 0.86 0.14
Approximate Cost (£/L) – 500 150 (129Xe- enriched)
25 (natural abundance)
aDiffusion coefficients taken from Chen et al33
5 of 15 birpublications.org/bjr Br J Radiol;94:20210207
BJRCurrent & future clinical perspectives of HP gas lung MRI
In the following sections, we review the respiratory disease areas 
where the technique has made a clinical research impact.
COPD & emphysema
Chronic obstructive lung disease (COPD) is a leading cause of 
mortality worldwide. Underdiagnosis, comorbidities and a lack 
of treatment access, all contribute to a significant healthcare 
burden.34 Emphysema is a form of COPD characterised by irre-
versible damage to the alveolar walls, leading to impaired gas 
exchange. Hyperpolarised gas MRI offers a sensitive means to 
characterise and stage emphysema, and may provide clinical 
utility in both early and late disease; in identifying early disease 
and suitable patients for early interventions, and also guiding 
targeted therapies such as endobronchial valves and lung volume 
reduction surgery.
Ventilation
HP gas ventilation MRI is highly sensitive to airway obstruction, 
and exhibits significant ventilation abnormalities in patients 
with emphysema, and COPD more broadly. The safety of HP 
gas ventilation MRI in smokers, patients with COPD and candi-
dates for lung volume reduction surgery (LVRS) is well docu-
mented.26,29 129Xe tends to exhibit increased VDP in participants 
with COPD when compared with3He,6,35 and regions of high 
129Xe VDP have been reported to correlate with emphysema on 
CT.36 Direct visualisation of collateral ventilation – a proposed 
response mechanism to compensate for airflow obstruction – has 
been reported using HP 3He.37 In a three- centre study, HP 3He 
ventilation MRI correctly categorised patients with COPD and 
revealed structure- function abnormalities upon comparison 
to CT.38 Complementary use of HP gas ventilation MRI and 
CT identified basal- lung predominant ventilation defects and 
apical- lung predominant CT emphysema, with utility for char-
acterisation of COPD grades.39 VDP is more sensitive to bron-
chodilator therapy in COPD than the gold- standard spirometry 
measurement of airflow obstruction; FEV1 (forced expiratory 
volume in 1 sec).40 Furthermore, HP gas ventilation MRI can 
depict the regional heterogeneity in bronchodilator response 
over the lungs, whereas spirometry measurements only provide 
information on the whole- lung average function. Moreover, 
HP gas MRI ventilation metrics show improved sensitivity to 
longitudinal lung function decline in COPD when compared 
to FEV1.
41 In a comprehensive single- site study of several MRI 
and CT biomarkers, only VDP longitudinal change correlated 
with St. George’s Respiratory Questionnaire on COPD quality of 
life.42 HP gas ventilation MRI is predictive of exacerbations in 
mild/moderate COPD43 and when combined with other imaging 
metrics such as ADC (see below), is predictive of FEV1 decline 
in smokers.44 Quantitative ventilation MRI with HP gases holds 
some promise for guiding LVRS45 and via the visualisation 
of collateral ventilation, is likely to have clinical utility for this 
purpose in the future. Moreover, the method may be useful in 
aiding the differentiation of asthma from COPD patients with 
pre- and post- bronchodilator reversibility ventilation imaging46 
alongside spirometric evaluation.
Figure 4. Patient A (13 years): clinical diagnosis of PCD; 
referred due to questionable clinical benefit of their stand-
ard physiotherapy. At baseline, spirometry showed a mixed 
obstructive/restrictive defect, suggesting an obstructive 
pattern with a significant gas- trapping component. Pre- 
physiotherapy 129Xe ventilation images (a) show clear evi-
dence of ventilation defects in the lung bases at baseline. 
Physiotherapy was performed using a PEP device. Post- 
physiotherapy 129Xe MRI (b) exhibited a marked reduction in 
the degree of ventilation defects, although some abnormali-
ties remained. Whilst VDP decreased from 9.0 to 3.5%, there 
was no clear change in VHI. Post- physiotherapy spirometry 
showed an increase in FEV1 of 8.4%, but no change in FVC. 
Complementary 1H SPGR imaging at RV (far right panel) 
indicated a visible decrease in gas trapping in the locations 
where ventilation defects improved, though some remaining 
gas trapping was evident. Complementary structure- function 
(1H-129Xe) MRI helped assess the benefits of performing the 
physiotherapy regime in this patient. Despite small improve-
ments in FEV1, a clear improvement in regional ventilation and 
a significant reduction in VDP was observed. FVC, forced vital 
capacity; PEP, positive expiratory pressure; VDP, ventilation 
defect percentage.
Figure 5. Patients B and C: Two patients with a clinical diag-
nosis of Fanconi Anaemia who had previously received a 
bone- marrow transplant. Both patients presented with simi-
lar symptoms of shortness of breath on exertion. Due to the 
underlying diagnosis and ionising radiation risk, the clinical 
team were reluctant to request a clinical CT. Both patients 
reported respiratory symptoms. Patient B (5 years) was una-
ble to perform spirometry with adequate technique. Patient 
C had normal spirometry and TLCO. These patients exhibited 
quite different patterns of underlying ventilation; Patient B had 
significant ventilation defects present throughout the lungs, 
whilst Patient C exhibited homogeneous ventilation. Patient 
B therefore had underlying respiratory pathology matching 
the documented symptoms, whilst Patient C had normal 
spirometry, TLCO and 
129Xe ventilation MRI. The MR images in 
these two similar cases demonstrated different outcomes and 
allowed bespoke management plans to be created.
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Alveolar microstructure
In patients with emphysema, alveolar tissue destruction leads 
to less- restricted (freer) diffusion and in- turn, an elevation 
in the global mean value of ADC; both 3He9,47 and 129Xe6,35,48 
ADC values are approximately twice that in healthy lungs. HP 
gas diffusion biomarkers agree well with the histologically- 
derived alveolar mean linear intercept (Lm) – the gold- standard 
measurement of alveolar size – in ex vivo human lungs.49–51 In 
addition, significant correlations between diffusion biomarkers 
and existing clinical measures for diagnosing and quantifying 
emphysema,52–55 including FEV1,
6,47,56 transfer factor of the 
lungs for carbon monoxide (TLCO)
6,35,48 and quantitative CT 
measures35,56–58 have been reported. When compared to CT 
mean lung density and emphysema index (−950 HU), ADC is 
more effective in separating patients with COPD and healthy 
controls, and correlates more strongly with TLCO.
38,59 The sensi-
tivity of HP gas diffusion- weighted MRI in detecting early/mild 
emphysematous lung disease has clinical promise. Diffusion 
biomarkers are significantly elevated in ex- smokers with COPD 
compared to age- matched never- smokers.56,60–62 Moreover, 
asymptomatic smokers (with normal spirometry) demonstrate 
subclinical differences to never- smokers; more heterogeneous 
distribution of ADC62,63 and reduction in alveolar sleeve depth 
(outer radius of the alveolar shell when modelling acinar airways 
as cylinders).61 Diffusion biomarkers also demonstrate sensi-
tivity to age- related acinar changes or senile “emphysema”64 
and show increased alveolar enlargement from childhood65 to 
adulthood.66–68 HP gas diffusion- weighted MRI is well- suited to 
longitudinal monitoring of COPD/emphysema disease progres-
sion as it is non- ionising. In ex- smokers with COPD, significant 
increases in ADC were observed after 2 years in the absence 
of significant change in FEV1.
41 The development of quantita-
tive metrics such as a HP gas MRI emphysema index58 shows 
promise for longitudinal studies as an easily- interpretable metric 
of emphysema severity with comparable diagnostic performance 
to CT- based emphysema indices and TLCO. Recent developments 
in spatial co- registration of images from HP diffusion- weighted 
MRI and CT have facilitated quantitative multi parametric 
response mapping (mPRM),69 which has revealed subclinical 
emphysema and small airways disease in ex- smokers without 
COPD that was not detectable with CT or MRI alone.70
Figure 7. Patient E: clinical diagnosis of CF monitored longi-
tudinally. At the patient’s routine clinical review, a chest X- ray 
and CT showed a right- upper lobe collapse and the patient 
was diagnosed with ABPA. After standard clinical manage-
ment, a repeat CT scan at 6 months was performed, which 
still showed the right- upper lobe collapse. At this stage, the 
patient had never reported any clinical symptoms and spirom-
etry had always remained unchanged at 90—95% predicted. 
The patient was therefore referred for MRI assessment of 
both ventilation and structure. A large ventilation defect was 
present in the right- upper lobe on ventilation MRI and did not 
ventilate at TLC, suggesting complete obstruction. 1H MRI 
images depicted the cause of the ventilation defect; a large 
mass of mucus- filled airways in the right- upper lobe. Upon 
reviewing these images, the clinical team decided to perform 
a bronchoscopy and repeat the MRI assessment. Repeat MRI 
was performed approximately 2 weeks post- bronchoscopy 
and showed that the large ventilation defect remained at end 
inspiratory tidal volume, but with some improved ventilation 
compared with pre- bronchoscopy, especially at TLC. 1H struc-
tural MRI demonstrated the removal of a large mass of mucus, 
though the mucus- affected airways remained damaged and 
functionally impaired. This case study highlights the comple-
mentary nature of 129Xe functional and 1H structural MRI and 
their promise in clinical assessment of bronchoscopy success 
as an alternative to repeat CT, especially when spirometry has 
limited clinical value. Key: from left- to- right; 129Xe ventilation 
MRI at end inspiratory tidal volume, 129Xe MRI at TLC, 1H ultra- 
short echo MRI, 1H spoiled gradient echo MRI at TLC. ABPA, 
allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; 
TLC, total lung capacity.
Figure 6. Patient D: clinical diagnosis of non- CF bronchiec-
tasis. The patient suffered from a chronic productive cough 
and amongst other treatments had a two- week course of IV 
antibiotics three months prior to referral for MRI. The patient’s 
FEV1 was static at >90%-predicted and historically did not 
change after antibiotics, making it difficult to determine the 
treatment efficacy. The patient was therefore referred for 
pre- and post- therapy ventilation MRI during their next two- 
week course of IV antibiotics. Large ventilation defects were 
evident in both lungs in baseline ventilation images (FEV1 = 
94%). Post- therapy, the patient’s FEV1 decreased to 89%-pre-
dicted, whilst ventilation images exhibited almost complete 
resolution of the large ventilation defects that were present 
at baseline (white arrows), although a new ventilation defect 
was present in the basal right lung (grey arrow). These images 
helped reassure the clinical team as to the efficacy of the cur-
rent treatment regime. This case highlights the sensitivity and 
benefit of regional lung function assessment offered by HP 
gas MRI in children on therapy, and the relative insensitivity of 
FEV1 to detect these changes. CF, cystic fibrosis;
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Interstitial lung disease
Interstitial lung disease (ILD) includes a heterogenous range of 
chronic lung conditions characterised by inflammation and/or 
scarring of the lung interstitium. Idiopathic pulmonary fibrosis 
(IPF) – one of the most common ILDs – is a progressive, ultimately 
fatal disease of unknown aetiology. ILD is usually characterised 
as a restrictive lung function disorder most commonly assessed 
by the spirometry metric, forced vital capacity (FVC). Imaging – 
particularly high- resolution CT (HRCT) – plays a key role in the 
diagnosis of IPF and its distinction from other ILDs. However, the 
reproducibility and sensitivity of FVC and TLCO to detect lung 
disease remains challenging, and most CT scans remain quali-
tative. HP 129Xe MRI, alongside quantitative HRCT is poised to 
play an important future role offering objective, reproducible, and 
sensitive imaging biomarkers, in the monitoring of ILD progres-
sion, prognosis and assessment of response to novel treatments.
Gas exchange
HP 129Xe MRS provides sensitive global metrics of gas exchange, 
such as the ratio of 129Xe MR signal in the RBCs to that in the 
TP (RBC:TP), which is significantly reduced in patients with 
IPF compared to healthy volunteers (p < 0.0002)16 and strongly 
correlates with TLCO. A pilot study using a 
129Xe time- resolved 
spectroscopic technique reported a statistically significant differ-
ence in alveolar septal thickness between healthy volunteers 
and patients with IPF and scleroderma (SSc), but no distinction 
between patient groups.17 Recently, 129Xe MRS was reported to 
have improved sensitivity to 12 month change in patients with 
IPF (p = 0.001) compared to FVC (p = 0.048) and TLCO (p = 
0.881).71 Whilst MRS provides a simple, sensitive global metric, 
regional gas exchange impairment in IPF can be visualised by HP 
129Xe spectroscopic imaging methods.13,21,72 Regions of reduced 
RBC transfer (RBC:Gas or RBC:TP) are observed predominantly 
in peripheral and basal lung regions, corresponding spatially 
with fibrosis on CT18,72 though correlation with CT fibrosis 
scoring has been weak to date.72 HP 129Xe gas exchange imaging 
metrics correlate strongly with TLCO
13,21,72 and show sensitivity 
to longitudinal IPF disease progression.73 HP 129Xe MRI offers a 
means to discriminate gas exchange impairment resulting from 
tissue thickening (TP:Gas) and other mechanisms, and has been 
utilised to characterise cardiopulmonary function in a range 
of disorders including COPD, IPF, left heart failure (LHF) and 
pulmonary arterial hypertension (PAH).74 A novel means to 
quantify cardio- pulmonary- vascular involvement via detecting 
cardiogenic oscillations in 129Xe RBC MR signal by spectros-
copy15 and imaging75 has revealed increased modulation of 
RBC signal in IPF.13,75 Increased RBC signal oscillations were 
also found in patients with LHF, suggesting changes in capillary 
blood volume during the cardiac cycle and secondary to post- 
capillary PH.74
Figure 8. Patient F: LVRS case study. 59- year- old ex- smoker 
with GOLD Stage 3 COPD, with significant limitation to daily 
life and severe hyperinflation. The patient had completed pul-
monary rehabilitation and was under consideration for lung 
volume reduction with endobronchial valves and a comple-
mentary HP gas MRI and CT clinical work- up was requested. 
a. HP 3He ventilation MRI, showing no ventilation in the right 
upper lobe and reduced ventilation in the left upper lobe. b. 
Dynamic contrast enhanced perfusion MRI, showing no perfu-
sion in the upper lobes. C. Unenhanced CT image, indicating 
upper lobe- predominant bullous emphysema. D. 3He delayed 
ventilation images (three time- points during the same breath- 
hold), showing wash- in of MRI signal in the right upper lobe 
over time, consistent with collateral ventilation, which was 
confirmed by Chartis (gas catheter bronchoscopy). Based on 
these images, a decision was made to insert endobronchial 
valves into the left upper lobe and successful lobar collapse 
was seen post- procedure. After the procedure, the patient 
reported a significant improvement in symptoms and was 
able to perform the usual activities of daily living. The com-
plementary use of multimodality imaging in the work- up for 
this LVRS candidate helped to prevent a likely unsuccessful 
right- sided procedure and provided reassurance that the left 
upper lobe was a viable target. COPD, chronic obstructive 
pulmonary disease; LVRS, lung volume reduction surgery.
Figure 9. Patient G: difficult asthma in a patient with normal 
spirometry. Patient was diagnosed with atopic eosinophilic 
asthma with a high symptom burden yet normal spirome-
try. Medications at the time of the clinically requested MRI 
scan were extensive; including mepolizumab 100 mg every 4 
weeks, flutiform 250/10 two puffs twice a day, prednisolone 
5mgs once daily and tiotropium. Mepolizumab was seen to 
somewhat alleviate their asthma symptoms and reduced the 
number of courses of steroids resulting in a marked improve-
ment in quality of life. However, a lower zone wheeze remained 
and despite long- term steroids, they still required 4—5 rescue 
courses of additional prednisolone in the previous 2 months. 
Ventilation MRI showed small and moderate defects and as 
a result, the decision was made to intensify patient therapy.
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There have been no published reports of the use of HP gas venti-
lation MRI in ILD, however, we note that gas exchange imaging 
techniques inherently acquire (low- resolution) ventilation 
images without the need for a separate breath- hold. Recently, HP 
3He gas diffusion- weighted MRI revealed that both ADC and 
LmD correlate with TLCO, carbon monoxide transfer coefficient 
(KCO) and regional fibrosis on CT in patients with IPF.
76 LmD 
increased significantly over 12 months, whilst other metrics 
did not. Increased ADC and LmD measurements may reflect 
reduced acinar integrity due to microstructural changes in the 
lung, secondary to fibrosis. We anticipate the complementary use 
of HP gas MRI techniques alongside novel methods for quantita-
tive CT that show prognostic value in IPF,77 to reveal the mech-
anisms behind the observed changes in alveolar microstructure, 
and further understand gas exchange structure- function charac-
teristics. Furthermore, the unique ability to measure gas transfer 
limitation when combined with DCE perfusion MRI for direct 
quantitative assessment of lung perfusion, provides unique 
insight in to distinguishing diffusion block from perfusion 
deficit. This powerful combination will be of use in phenotyping 
the overlap of interstitial and pulmonary vascular lung patho-
physiology, and recent pilot studies have shown these methods to 
be sensitive to such mechanisms in post- COVID lung disease.78
Asthma
One of the most common respiratory conditions worldwide, 
asthma is a chronic airway disease that accounts for a UK health- 
care burden of at least £1.1 billion each year.79 Clinical efforts 
Figure 11. Patient I: Undifferentiated airways disease. A 
71- year- old ex- smoker with progressive breathlessness on 
minor exertion and hypothyroidism. Spirometry was supra-
normal with no acute reversibility to salbutamol. No gas 
trapping or hyperexpansion. Normal echocardiogram. CT 
showed minor emphysema, disproportionate to the extent of 
abnormality in gas transfer (TLCO 47.9%). No acute or chronic 
clot on CT pulmonary angiography. 1H perfusion MRI showed 
minor abnormalities. HP gas ventilation MRI showed multiple 
predominantly segmental ventilation defects most prominent 
in the right upper lobe (white arrows). MRI determined that 
there were substantial ventilation abnormalities despite nor-
mal spirometry, alongside relatively normal perfusion, and 
therefore poor local V/Q matching.
Figure 12. Patient J: Referred around ten months after having 
COVID-19. The patient had an acute infection post- COVID and 
persistent breathlessness; “long- COVID”. 1H structural and 
perfusion imaging revealed no apparent abnormalities (a). HP 
129Xe ventilation imaging showed a homogeneous pattern of 
ventilation (b) with no substantial defects, however, signifi-
cant gas transfer impairment was indicated by a mean RBC/
TP (mean of map in c.) of 0.15 (c.f. healthy ~0.47) and elevated 
TP/Gas. Of topical note, preliminary reports of HP gas MRI in 
patients post- COVID-19 have been recently published78 and 
similar studies are underway at our centre to investigate long- 
term effects on lung function. RBC, red blood cell; TP, tissue 
and blood plasma.
Figure 10. Patient H: Patient in their 60s with difficult ILD. Also diagnosed with fatty liver disease and cirrhosis. CT showed some 
evidence of unclassifiable ILD and gas transfer was extremely low (TLCO of 26%-predicted). The patient did not meet the diag-
nostic criteria for hepatopulmonary syndrome and had been assessed for pulmonary hypertension. A 1H and HP gas MRI work- up 
was requested to determine the relative contribution of any ILD or PH or shunting due to hepatopulmonary syndrome, to inform 
a decision regarding liver transplantation. There was no evidence of shunt on dynamic contrast enhanced MRI angiography. There 
was mild- to- moderate ILD in the lower lobes with reticular disease seen on UTE (a), normal perfusion on DCE MRI (b) and no 
substantial ventilation defects on 129Xe ventilation imaging (c). The mean RBC/TP (whole- lung average of the map in d.) was low 
(0.13 compared to 0.47 in healthy volunteers), and RBC/gas was similarly low (0.0017 compared to 0.0036), while TP/gas was 
high (0.0134 compared to 0.0075), indicating severe interstitial thickening/endothelial diffusion- block and significant gas transfer 
limitation. MRI assessment supported pulmonary function gas transfer results and confirmed that gas exchange deficiency was 
the predominant disease process despite discordance with the apparent severity of ILD visible on CT. Key: from left- to- right: a. 1H 
UTE MRI, b. contrast- enhanced perfusion, c. Low resolution 129Xe ventilation imaging (obtained during a gas exchange imaging 
acquisition), d. Map of RBC/TP signal intensities, a metric of gas exchange. ILD, interstitial lung disease; RBC, red blood cell; TP, 
tissue and blood plasma; UTE, ultrashort time.
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are focused on improving patient management and preventative 
medicine.80 There is significant variability in the clinical, physio-
logical and pathological presentation81 and different phenotypes 
can have different responses to therapy.82 In asthma, hyperpo-
larised gas MRI offers a unique, sensitive means to visualise the 
extent of airways disease, its reversibility, and the functional 
response of the lungs to therapy and may find future utility in 
assessment of novel biologics for personalised medicine.
Ventilation defects visualised by hyperpolarised gas MRI, 
depicting regions of airflow obstruction in asthma, increase 
with clinical asthma severity,83,84 and are associated with age, 
airway hyperresponsiveness and airway remodelling.85 Several 
studies have reported correlations between numbers of venti-
lation defects (or VDP) and spirometric indices, including 
FEV1
83,84,86–89 and FEV1/FVC.
83,84,86,87,89,90 VDP increases after 
methacholine (bronchoprovocation) challenge91 or exercise90 
and decreases after bronchodilator inhalation.91 Ventilation 
defects have also been associated with increased airway resis-
tance,85,91 fractional exhaled nitric oxide (FeNO; a marker of 
inflammation)85,91 and lung clearance index (LCI), a measure 
of ventilation heterogeneity.92 Patients with severe, poorly- 
controlled asthma and low quality of life have been reported to 
have increased ventilation heterogeneity and VDP,92 and in a 
larger population with a wide range of severity, VDP correlated 
inversely with asthma control.87 Increased VDP is associated 
with asthma exacerbations, leading to hospitalization (including 
in patients with mild/moderate disease)86 and with exacerbation 
frequency over 2 years following MRI.87
HP gas MRI ventilation abnormalities have also been reported to 
correlate with blood eosinophil count,86,87 post- bronchodilator 
sputum eosinophils,93 and more invasive, yet sensitive metrics 
such as localised bronchoscopy and neutrophils in bronchoalve-
olar lavage fluid.94 HP gas MRI and CT provide highly comple-
mentary information in the identification of structure- function 
phenotypes of asthma. In particular, regions of air trapping94 and 
mucous plugging95 on CT have been reported to show significant 
overlap with ventilation defects. In a recent study, higher VDP in 
patients with >10 missing airway subsegments quantified by CT 
total airway count was reported.96 Several studies have revealed 
a spatial heterogeneity in location of ventilation abnormalities 
in patients with asthma at baseline,84,90,94 and increased abnor-
malities in posterior regions following exercise.90 Despite the 
variable nature of airflow obstruction in asthma, the location 
of ventilation defects often persists over time.97 A recent 6 year 
follow- up study found that ventilation defects remained local-
ised, and did not significantly change in size in ~70% of patients 
with asthma; in the remaining ~30% of patients, defects were 
larger at follow- up.98
HP gas MRI has been utilised to visualise not only response to 
bronchodilator,89,99 but also to novel and existing treatments, 
including bronchial thermoplasty100 and the anti- inflammatory 
drug montelukast.90 A recent report demonstrated that HP gas 
ventilation MRI can be used to guide bronchial thermoplasty 
treatment.101 In the past year, the first report of HP gas MRI 
to assess biologic treatment of persistent post- bronchodilator 
ventilation abnormalities93 in severe asthma with uncontrolled 
sputum eosinophilia was published102; a first step towards HP 
gas MRI for personalised medicine. In our recent experience of 
using 129Xe ventilation MRI clinically in a real- world population 
of patients with difficult asthma, we found that it provided unique 
information on disease severity and bronchodilator reversibility, 
which aided in the clinical evaluation of asthma.103 Evidence of 
airways obstruction on MRI supported the use of further treat-
ment in patients where the clinical picture was unclear, whilst 
conversely, well- preserved ventilation on MRI alongside poor 
spirometry and/or symptom control suggested the possibility of 
coexisting breathing control issues or laryngeal disorders.
Paediatric asthma is likely to be a future area of research focus.104 
Of particular note, the safety and tolerability of HP gas MRI in 
66 children with asthma reported no serious adverse events and 
three minor adverse events (2.3%; including headache, dizzi-
ness and mild hypoxia).105 Preliminary reports have shown that 
VDP and the number of defects per slice are predictive of asthma 
outcomes, including clinical asthma severity, corticosteroid use, 
and health- care utilisation.106,107 We anticipate future use of HP 
gas ventilation MRI in the identification of patients prone to 
exacerbations, and/or those suitable for personalised treatments.
Cystic fibrosis
Cystic fibrosis (CF) is a hereditary disease caused by a muta-
tion in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene. Lung disease is the primary cause of morbidity and 
mortality in patients with CF, and is progressive throughout life, 
beginning soon after birth. Significant scientific breakthroughs 
have enabled the production of highly effective CFTR modulator 
therapies that are now becoming available for a large proportion 
of patients,108 however, the health- care burden of CF remains 
high, and clinical care is often complex. There is a clinical need 
to be able to identify early changes in lung disease to prevent 
further deterioration. Hyperpolarised gas MRI techniques may 
be ideally placed to identify early disease and moreover provide a 
sensitive, safe means to monitor longitudinal disease progression 
and therapy response.
HP gas ventilation MRI procedures are safe and well- tolerated in 
adult and paediatric patients with CF.31 Ventilation abnormali-
ties in patients with CF have been investigated by both static109 
and dynamic110 MRI and abnormalities typically present as 
heterogeneous and patchy. The technique is repeatable, with a 
minor change in VDP on the same day111 and at 7 day and 4 
week follow- up, and ventilation defects located in the same 
spatial regions.112,113 Zonal analysis of ventilation MRI metrics 
shows good agreement with HRCT score in adults with CF.114 
CF exhibits several characteristic structural abnormalities (e.g. 
mucus plugging, bronchiectasis, bronchial wall thickening) and 
recently, some agreement in the spatial location of structural 1H 
MRI and functional 129Xe ventilation MRI abnormalities has 
been reported.115 When combined, these methods may offer a 
non- invasive means to predict clinical outcomes in paediatric 
CF.116 VDP exhibits a strong correlation with LCI,5,117 a metric 
of ventilation heterogeneity – derived from the multiple breath 
washout (MBW) pulmonary function test – that shows greater 
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sensitivity than conventional spirometry in the detection of mild 
CF.118 Furthermore, an analogous metric of ventilation heteroge-
neity to LCI (a so- called ventilation heterogeneity index (VHI)) 
can be derived from HP gas ventilation MRI, and exhibits good 
agreement with MBW metrics including LCI.5 Recently, an 
imaging analogue of the MBW pulmonary function test has been 
shown to be feasible using multiple breath HP gas MRI in CF.119
Ventilation abnormalities on HP gas MRI appear to be a char-
acteristic of the earliest measurable changes to lung function in 
CF. Several studies have demonstrated how in patients with clin-
ically stable lung disease and normal values for FEV1, that venti-
lation abnormalities are already present.20,117,120 The sensitivity 
of ventilation MRI to CF pathophysiology has been found to be 
superior to CT, conventional MRI or LCI, and in several cases, 
ventilation abnormalities on MRI in the absence of abnormality 
on CT have been observed.20 Several studies have reported the 
high sensitivity of HP gas ventilation MRI to detect a therapeutic 
response in CF, such as bronchodilator and airway clearance 
treatment,121 chest physiotherapy,122,123 exercise,124 antibiotics125 
and ivacaftor,126 and we anticipate clinical utilisation in this 
manner in the future. Moreover, recent reports have highlighted 
the high sensitivity of HP gas ventilation MRI to mild func-
tional change in CF over a 1—2 year period where spirometry 
(FEV1) showed no significant change.
111,127 In particular, VDP 
was found to have a higher median longitudinal change than LCI 
and FEV1 and relative changes in VHI significantly correlated 
with those of LCI.111 In the same report, based on observational 
follow- up of CF patients at an average of 16 months, thresholds 
for significant clinical changes in VDP were reported, as well as 
estimates for clinical trial population sizes.111
Clinical utility: our preliminary experience
HP gas MRI holds the potential to play a clinical role in a range 
of pulmonary conditions including and additional to those listed 
above. In 2015, our centre was authorised by the UK MHRA to 
manufacture HP gases for clinical MRI indications, and since 
then we have had more than 500 referrals from clinicians around 
the UK, to assist with difficult diagnoses and provide additional 
clinical information. Qualitative imaging data is generated as a 
technical report (see Supporting Information) that is used as the 
basis of a multidisciplinary team (MDT) meeting composed of: 
respiratory physicians, adult/paediatric chest radiologists, MRI 
physicists, physiologists and radiographers, and from which 
a qualitative radiological report is also drawn. In the future, 
defining an accurate clinical reporting terminology of these 
images will likely require consensus- building work with system-
atic qualitative radiological interpretation of the imaging features 
observed. In terms of clinical reporting, we believe it is critical to 
report HP gas MR imaging biomarkers as non- subjective, quan-
titative metrics, and, for clinical utility, to ensure that images 
are interpreted within an MDT setting so that all staff involved 
build- up experience with the images and metrics.
In the following, we present several patient case studies that 
highlight the clinical utility of the HP gas method.
Paediatric lung disorders
Of our referrals to date, around 20% have been paediatric 
patients. Many of these patients had limited clinical imaging 
prior to referral due to concerns over ionising radiation expo-
sure. Example clinical case studies are shown in the following 
figures (Figure 4, Figure 5, Figure 6, Figure 7).
Adult lung disorders
Example clinical case studies are shown in the following figures 
(Figure 8, Figure 9, Figure 10, Figure 11, Figure 12).
Future perspectives
HP gas MRI is a high sensitivity, safe and tolerable, non- ionising 
method for interrogation of pulmonary function, with avenues 
for clinical application in; (i) early (subclinical) detection, (ii) 
longitudinal monitoring, (iii) evaluation of treatment response. 
The method has great potential in drug development studies 
and is already established in pharmaceutical research and devel-
opment pipelines. From a clinical perspective its use in char-
acterisation of regional lung function in rare and difficult lung 
diseases, where CT and lung function tests have limited sensi-
tivity and utility, are the likely areas of immediate clinical impact.
From a practical perspective, there remains a need for inter-
vendor, inter site standardisation of HP gas MRI techniques – 
in particular, novel gas exchange imaging methods – that will 
be facilitated by multi site studies over the next few years (see: 
https:// cpir. cchmc. org/ XeMRICTC). In parallel, improvements 
in the availability of regulatory approved gas polarisation appa-
ratus will allow increased accessibility of the technique in the 
future. Although an increasing number of multinuclear capable 
MR scanners are sold each year, recognition of the clinical poten-
tial of the technique by the MRI scanner vendors is still required 
to expedite further dissemination of this technology.
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